Related Experiment Video
Updated: Jun 12, 2026
Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development
Published on: June 19, 2018
Adjuvants for cancer vaccines
Thomas W Dubensky1, Steven G Reed
1Immune Design Corporation, 1124 Columbia St., Ste. 700, Seattle, WA 98104, United States.
Recent FDA approvals of sipuleucel-T and Cervarix highlight cellular immunotherapy and adjuvants. This review examines novel molecular adjuvants and formulations for developing new cancer vaccines.
Area of Science:
- Immunology
- Oncology
- Vaccinology
Background:
- Cellular immunotherapy, exemplified by sipuleucel-T (Provenge) for prostate cancer, is gaining traction.
- Adjuvants enhance immune responses, crucial for vaccine efficacy, as seen with Cervarix for HPV.
- Recent FDA approvals signal a resurgence in therapeutic cancer vaccine development.
Purpose of the Study:
- To review novel molecularly defined adjuvants and formulations.
- To discuss their application in developing therapeutic cancer vaccines.
- To highlight recent advancements in cancer immunotherapy.
Main Methods:
- Review of scientific literature on cellular immunotherapy and vaccine adjuvants.
- Analysis of recent FDA-approved vaccines like sipuleucel-T and Cervarix.
- Examination of emerging adjuvant technologies and their impact on immune response.
Main Results:
- Sipuleucel-T supports cellular immunotherapy for cancer.
- Cervarix demonstrates broad immune response with monophosphoryl lipid A (MPL) adjuvant.
- Novel adjuvants show promise for enhancing therapeutic cancer vaccines.
Conclusions:
- Recent vaccine approvals validate cellular immunotherapy and adjuvant roles.
- New molecular adjuvants are key to advancing therapeutic cancer vaccine development.
- Increased interest and investment are expected in this field.
More Related Videos
07:32Evaluating the Immune Response of a Nanoemulsion Adjuvant Vaccine Against Methicillin-Resistant Staphylococcus aureus (MRSA) Infection
Published on: September 1, 2023
06:02Cationic Nanoemulsion-Encapsulated Retinoic Acid as an Adjuvant to Promote OVA-Specific Systemic and Mucosal Responses
Published on: February 23, 2024
Related Concept Videos
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:51Vaccinations
01:21Vaccines